Last reviewed · How we verify
MK0524A, /Duration of Treatment : 4 Weeks
MK0524A, /Duration of Treatment : 4 Weeks is a GPR109A agonist Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides.
MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides.
MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides. Used for Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides.
At a glance
| Generic name | MK0524A, /Duration of Treatment : 4 Weeks |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | GPR109A agonist |
| Target | GPR109A |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
MK0524A selectively binds to the GPR109A (niacin) receptor on immune cells and adipocytes, triggering signaling cascades that increase HDL-C production and reduce triglyceride levels. This mechanism mimics the beneficial lipid-modifying effects of niacin without the flushing side effects associated with direct niacin administration, as it avoids activation of GPR109B on keratinocytes.
Approved indications
- Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides
Common side effects
- Flushing
- Gastrointestinal disturbances
- Hyperuricemia
Key clinical trials
- MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) (PHASE2)
- Effect of MK0524A on Flushing Caused by Niacin (0524A-056) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0524A, /Duration of Treatment : 4 Weeks CI brief — competitive landscape report
- MK0524A, /Duration of Treatment : 4 Weeks updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about MK0524A, /Duration of Treatment : 4 Weeks
What is MK0524A, /Duration of Treatment : 4 Weeks?
How does MK0524A, /Duration of Treatment : 4 Weeks work?
What is MK0524A, /Duration of Treatment : 4 Weeks used for?
Who makes MK0524A, /Duration of Treatment : 4 Weeks?
What drug class is MK0524A, /Duration of Treatment : 4 Weeks in?
What development phase is MK0524A, /Duration of Treatment : 4 Weeks in?
What are the side effects of MK0524A, /Duration of Treatment : 4 Weeks?
What does MK0524A, /Duration of Treatment : 4 Weeks target?
Related
- Drug class: All GPR109A agonist drugs
- Target: All drugs targeting GPR109A
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides
- Compare: MK0524A, /Duration of Treatment : 4 Weeks vs similar drugs
- Pricing: MK0524A, /Duration of Treatment : 4 Weeks cost, discount & access